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Abstract
Background: The proinflammatory cytokine interleukin-1 (IL-1) is known to play an important
role in the carcinogenesis of breast cancer. Although IL-1 gene polymorphisms were reported to
be associated with increased risk of breast cancer, their influence on survival of Caucasian breast
cancer patients remains to be shown.
Methods: We studied the influence of four common gene polymorphisms (IL1A -889C/T, IL1B -
511C/T, IL1B +3953E1/E2, and IL1RN long/2) of the IL-1 family on survival in 262 Caucasian patients
with breast cancer by univariate and multivariate survival analysis. The combined effect of the four
gene polymorphisms on overall survival was studied by haplotype analysis.
Results: In the present study 38 cases of cancer related death and a median time of follow-up
(range) of 55.3 (0.4–175.8) months was observed. IL1RN  2/2 (homozygous mutant) gene
polymorphism was associated with shortened disease free and overall survival in a univariate (p =
0.001 and p = 0.01, respectively) and multivariate analysis (p = 0.002, Odds Ratio [95% Confidence
Interval] = 3.6 [1.6–8.0] and p = 0.05, Odds Ratio = 3.0 [1.1–9.3], respectively). Presence of the
homozygous mutant genotype of the IL1A -889 and IL1B +3953 gene polymorphism was associated
with overall survival in the univariate (p = 0.004 and p = 0.002, respectively), but not in the
multivariate analysis. No association was observed between all possible haplotype combinations
and overall survival.
Conclusion: Carriage of the mutant alleles of IL1RN was independently associated with shortened
disease free and overall survival rates in Caucasian patients with breast cancer.
Background
The interleukin-1 (IL-1) family consists of the cytokines,
IL-1alpha (IL-1a), IL-1beta (IL-1b) and a specific receptor
antagonist (IL-1RA) [1]. IL-1a and IL-1b are involved in
various physiological and patho-physiological processes
such as modulating the host response to microbial inva-
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sion, inflammation, and tissue injury [2]. IL-1RA neutral-
izes IL-1 action by binding to the IL-1 receptors (IL-1RI
and IL-1RII) [3].
In addition to its role in inflammatory processes, IL-1 has
been extensively studied in various malignancies. Expres-
sion of IL-1 has been described in breast cancer tissue
[4,5] as well as several other tumor tissues [6,7]. Its pro-
duction and release by tumor cells results in an autocrine
and paracrine induction of prometastatic genes in human
breast cancer [8]. In vitro studies reported IL-1 to be cru-
cially involved in cell survival, proliferation, and angio-
genesis [6]. Recent studies suggested that IL-1 was
associated with more aggressive forms of breast cancer
[9,10].
The IL-1 gene cluster on chromosome 2q14.2 comprises 3
related genes within a 430-kilobase (kb) region, IL-1A, IL-
1B, and IL-1RN, which encode the pro-inflammatory
cytokines IL-1a, IL-1b, and their endogenous receptor
antagonist IL-1RA, respectively [11]. In vitro and in vivo
studies demonstrated that IL1-A and IL1-B gene polymor-
phisms [12,13] corresponded with altered IL-1a and IL-1b
protein expression, respectively [12,14]. Regarding the IL1
receptor antagonist, the IL1RN mutant allele 2 has been
repeatedly associated with changes of the IL-1RA protein
expression [15,16].
IL-1 polymorphisms have been investigated in a variety of
malignancies. They were associated with an increased risk
for ovarian [17], gastric [18], lung [19], and prostate can-
cer [20]. With respect to breast cancer, two recent studies
demonstrated an association between IL-1  polymor-
phisms and increased risk for the disease [21,22].
While other interleukin polymorphisms have been exten-
sively studied as prognostic markers in breast cancer
patients [23-25] little is known about the prognostic value
of IL-1  gene polymorphisms. In one study comprising
Tunisian patients with breast cancer the IL1A  TT
(homozygous mutant) genotype was associated with
impaired prognosis in patients with breast cancer [26].
To the best of our knowledge, we are the first to investigate
the prognostic value of gene polymorphisms within the
IL-1 family in Caucasian patients with breast cancer.
Methods
Two-hundred-sixty-two consecutive patients with breast
cancer treated between 1999 and 2001 at the Departments
of Obstetrics and Gynecology, Martin-Luther-University
Medical School, Halle-Wittenberg, Germany and Medical
University of Vienna, Vienna, Austria, were included in
our study. All of the participating patients were of Cauca-
sian origin and signed written consent. Approval for this
study was obtained by the Institutional Review Boards at
the Martin-Luther-University Medical School, Halle-Wit-
tenberg, Germany and the Medical University of Vienna,
Vienna, Austria.
Patients' data was collected by reviewing patients' files. Of
note, family history of breast cancer was documented only
in very few cases and therefore not included in our analy-
sis. Histological staging of breast cancer was performed
according to the current classification of the International
Union Against Cancer (UICC). All cases were reviewed by
an experienced pathologist, blinded to patients' clinical
data. Patients received surgery, chemotherapy, radiother-
apy, and endocrine therapy by standard protocols.
National guidelines were followed according to St. Gallen
recommendations in the respective years.
DNA was extracted from patients' blood. Pyrosequencing
and polymerase chain reaction (PCR) were performed
according to established protocols as described previously
[27].
After testing for normality using Kolmogorov-Smirnov
test, values are given as mean (standard deviation [SD]) or
median (range), where appropriate. Hardy-Weinberg
equilibrium was tested by chi-square tests comparing
observed and expected haplotype frequencies. Associa-
tions between polymorphisms and clinicopathological
parameters were calculated by chi-square tests – results are
given as p-value and Odds Ratio (OR) (95% Confidence
Interval [95%CI]). Due to multiple testing Bonferroni-
Holmes adjustment was performed. Parameters have been
calculated as followed: IL1A -889 (C/C and C/T vs. T/T),
IL1B -511 (C/C and C/T vs. T/T), IL1B +3953 (E1/E1 and
E1/E2 vs. E2/E2), IL1RN VNTR intron 2 (long/long and
long/2 vs. 2/2), tumor status (pT1 vs. pT2-4), tumor grade
(well differentiated vs. moderately and poorly differenti-
ated), lymph node involvement (yes vs. no), presence of
estrogen or progesterone receptor (positive vs. negative),
and patient's age at diagnosis (≤ 50 years vs. > 50 years).
Survival probabilities were calculated by the product limit
method of Kaplan and Meier. Differences between groups
were tested using the log-rank test. The results were ana-
lyzed for the endpoint of disease free and overall survival.
Survival times of patients without any evidence of recur-
rent disease or still alive at the time of last follow-up were
censored with the last follow-up date. A multivariate Cox
regression model was performed for disease free and over-
all survival comprising tumor status, tumor grade, lymph
node involvement, presence of estrogen or progesterone
receptor, and in the respective univariate analysis signifi-
cantly associated gene polymorphisms (i.e., IL1RN VNTR
intron 2 gene polymorphism in the disease free survival
analysis and IL1A -889C/T, IL1B +3953, and IL1RN VNTRBMC Cancer 2009, 9:78 http://www.biomedcentral.com/1471-2407/9/78
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intron 2 gene polymorphisms in the overall survival anal-
ysis).
Haplotype frequencies were calculated by using SAS/
Genetics software. Association between haplotypes and
breast cancer survival was calculated using a Cox regres-
sion model treating each haplotype as an independent
continuous variable.
We used the software SAS System (Version 9.1 SAS Insti-
tute Inc., Cary, NC) and SPSS (SPSS 11.0, SPSS Inc. Chi-
cago, IL) for statistical analysis. Two-sided p-values ≤ 0.05
were considered statistically significant.
Results
Patients' characteristics are given in Table 1 (Additional
file 1). Genotype and allele frequencies of the four inves-
tigated  IL-1  gene polymorphisms are given in Table 2
(Additional file 1). As previously published genotype dis-
tribution of all investigated gene polymorphisms was in
Hardy-Weinberg equilibrium [28]. The four investigated
polymorphisms were all in linkage disequilibrium (IL1A -
889 and IL1B -511: p = 0.0001, Lewontin's D' = 0.5; IL1B
-511 and IL1B +3953: p < 0.0001, Lewontin's D' = 0.7;
IL1B +3953 and IL1RN: p = 0.004, Lewontin's D' = 0.6).
IL1A -889, IL1B -511, IL1B +3953, and IL1RN were not
associated with clinicopathological parameters, i.e.,
tumor status (p = 0.5, p = 0.8, p = 0.2, p = 0.3), tumor
grade (p = 0.9, p = 0.9, p = 0.3, p = 0.3), lymph node
involvement (p = 0.6, p = 0.8, p = 0.8, p = 0.9), presence
of estrogen or progesterone receptor (p = 0.9, p = 0.7, p =
0.9, p = 0.9), and patient's age at diagnosis (p = 0.2, p =
0.4, p = 0.7, p = 0.8), respectively.
Survival analysis were calculated by performing univariate
Kaplan-Meier analysis and multivariate Cox-Regression
models to correct for established clinicopathological
parameters. Results are presented in Table 3 (Additional
file 1). In a univariate Kaplan-Meier analysis only IL1RN
gene polymorphisms was associated with disease free sur-
vival (Figure 1.), whereas IL1A -889, IL1B -+3953, and
IL1RN (Figure 2.) were associated with overall survival.
After correcting for established clinicopathological
parameters in a multivariate Cox-Regression model, the
IL1RN gene polymorphism was independently associated
with shortened disease free and overall survival.
Furthermore, the combined effect of the four gene poly-
morphisms on breast cancer survival was investigated by
haplotype analysis (Additional file – Table 4). No signifi-
cant associations between haplotypes and overall survival
were observed.
Discussion
In the present study, the IL1RN  long/2 gene polymor-
phism was independently associated with an unfavoura-
ble prognosis in breast cancer patients, while presence of
the mutant alleles of IL1A -889 and IL1B +3953 were only
associated with a shortened overall survival in a univariate
analysis. These findings are in line with a series of studies
that have found interleukin gene polymorphisms to be
associated with shortened overall survival in breast cancer
patients [23,25].
This is biologically plausible, as mutations of IL1A -889
and IL1B +3953 are thought to lead to increased IL-1 pro-
duction [12,14,15]. In comparison, the mutant IL1RN
allele has been reported to modify the binding on the IL1-
receptor, leading to a worse inhibition of the IL-1a and IL-
1b binding and subsequently to an increased IL-1 produc-
tion [29]. This might result in an unfavourable proinflam-
matory status and enhanced tumor aggressiveness, which
is likely to result in a shortened survival.
In addition to its potential as a prognostic marker, partic-
ularly IL1RN is of increasing interest with regard to thera-
peutic implications. Recently a recombinant human IL-1
receptor antagonist, has been approved to block the
proinflammatory effects of IL-1 in patients with rheu-
mathoid arthritis [30]. Experimental data based on mouse
models support the hypothesis that an IL-1 receptor
Disease free survival of patients with breast cancer broken  down by the IL1RN polymorphism Figure 1
Disease free survival of patients with breast cancer 
broken down by the IL1RN polymorphism. P denotes 
the log-rank test value.
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antagonist might also work as a therapeutic agent in neo-
plasms [30,31].
Of note, the exact mechanisms by which these four poly-
morphisms exert their effects on IL-1 levels remain still
unclear to date. In the present investigation, we focused
on the evaluation of IL-1 gene polymorphisms, and did
not plan to investigate serum levels of the IL-1 cytokines.
Interestingly, IL1RN was the only of three polymorphisms
that remained significant in the multivariate model,
which was performed to correct for potential confound-
ers. Despite this consistent association between IL1RN
and overall survival in a univariate and multivariate anal-
ysis, it has to be considered that seven variables were
included in the multivariate analysis with only 38 events
observed. The high number of variables was included in
the multivariate model as this is the only way to evaluate
an independent association between the respective gene
polymorphism and overall survival. In that case, however,
a random finding can not be completely ruled out. The
other two polymorphisms, IL1A -889 and IL1B +3953,
were only associated with shortened survival in a univari-
ate survival analysis. Therefore, it can not be ruled out that
these associations might result from unequal distribution
of well known prognostic factors, such as tumor stage,
lymph node involvement or tumor grade.
Of note, it was not feasible to evaluate the association
between IL-1 gene polymorphisms and family history of
breast cancer as this information was missing in the
majority of patients. Furthermore, we were unable to
investigate the association between IL-1 gene polymor-
phisms and distant metastases because of the limited
number of events (4 patients with distant metastases).
As all four IL-1 gene polymorphisms were in linkage dise-
quilibrium, we performed a haplotype survival analysis to
investigate whether there is a high risk haplotype combi-
nation. Interestingly, we were not able to identify such a
high risk haplotype combination, which might be caused
by the relatively high number of variables (n = 16) com-
pared to the number of events (n = 38 cancer related
deaths).
Conclusion
IL-1 has been reported to be crucially involved in cell sur-
vival, proliferation, and angiogenesis in cancer cells [6].
Moreover IL-1 secretion seems to be associated with a
more aggressive form of breast cancer [9,10]. IL-1 gene
polymorphisms were reported to be associated with an
increased risk of breast cancer [21,22]. They are thought to
increase IL-1 levels subsequently contributing to a proin-
flammatory environment. All of the four investigated IL-1
gene polymorphisms have been demonstrated to corre-
spond with altered IL-1 protein expression [12-16]. The
IL1RN gene polymorphism might be of prognostic value
as carriage of the two mutant alleles was independently
associated with shortened disease free and overall survival
in Caucasian patients with breast cancer.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
CG was critically involved in designing the study, statisti-
cal analysis, and drafted the manuscript. LH conceived of
the study, participated in the design of the study and
helped draft the manuscript. EK carried out molecular
genetic studies, contributed to acquisition of data, and
critically revised the manuscript. GH was involved in
design of the study, statistical analysis, and revision of the
methods section of the manuscript. SP was involved in
acquisition of the data, and interpretation of the data. RZ
participated in primer selection, provided biomolecular
expertise, carried out molecular analysis, and helped with
statistical analysis. HK partially conceived of the study
and participated in its design and coordination. AR was
substantially involved in the design of the study and draft-
Overall survival of patients with breast cancer broken down  by the IL1RN polymorphism Figure 2
Overall survival of patients with breast cancer bro-
ken down by the IL1RN polymorphism. P denotes the 
log-rank test value.
Months
60 48 36 24 12 0
O
v
e
r
a
l
l
 
S
u
r
v
i
v
a
l
1,0
,8
,6
,4
,2
0,0
    IL1RN long/long and long/2 
 
 
 
 
 
              IL1RN 2/2 
P=0.01 BMC Cancer 2009, 9:78 http://www.biomedcentral.com/1471-2407/9/78
Page 5 of 6
(page number not for citation purposes)
ing the manuscript. All authors read and approved to the
final manuscript.
Additional material
References
1. Ricote M, Garcia-Tunon I, Bethencourt FR, Fraile B, Paniagua R, Roy-
uela M: Interleukin-1 (IL-1alpha and IL-1beta) and its recep-
tors (IL-1RI, IL-1RII, and IL-1Ra) in prostate carcinoma.
Cancer 2004, 100:1388-1396.
2. Dinarello CA: Interleukin-1, interleukin-1 receptors and inter-
leukin-1 receptor antagonist.  Int Rev Immunol 1998, 16:457-499.
3. Sauer J, Renner U, Hopfner U, Lange M, Müller A, Strasburger CJ,
Pagotto U, Arzt E, Stalla GK: Interleukin-1 beta enhances inter-
leukin-1 receptor antagonist content in human somatotroph
adenoma cell cultures.  J Clin Endocrinol 1998, 83:2429-2434.
4. Cooke MM, McCarthy GM, Sallis JD, Morgan MP: Phosphocitrate
inhibits calcium hydroxyapatite induced mitogenesis and
upregulation of matrix metalloproteinase-1, interleukin-
1beta and cyclooxygenase-2 mRNA in human breast cancer
cell lines.  Breast Cancer Res Treat 2003, 79:253-263.
5. Miller LJ, Kurtzman SH, Anderson K, Wang Y, Stankus M, Renna M,
Lindquist R, Barrows G, Kreutzer DL: Interleukin-1 family
expression in human breast cancer: interleukin-1 receptor
antagonist.  Cancer Invest 2000, 18:293-302.
6. Wolf JS, Chen Z, Dong G, Sunwoo JB, Bancroft CC, Capo DE, Yeh
NT, Mukaida N, Van Waes C: IL (Interleukin)-1alpha promotes
nuclear factor-kappaB and AP-1-induced IL-8 expression,
cell survival, and proliferation in head and neck squamous
cell carcinomas.  Clin Cancer Res 2001, 7:1812-1820.
7. Kimura H, Inukai Y, Takii T, Furutani Y, Shibata Y, Hayashi H,
Sakurada S, Okamoto T, Inoue J, Oomoto Y, Onozaki K: Molecular
analysis of constitutive IL-1alpha gene expression in human
melanoma cells: autocrine stimulation through NF-KB acti-
vation by endogenous IL-1alpha.  Cytokine 1998, 10:873-879.
8. Nozaki S, Sledge GW Jr, Nakshatri H: Cancer cell-derived inter-
leukin 1 alpha contributes to autocrine and paracrine induc-
tion of prometastatic genes in breast cancer.  Biochem Biophys
Res Commun 2000, 275:60-62.
9. Singer CF, Hudelist G, Gschwantler-Kaulich D, Fink-Retter A, Mueller
R, Walter I, Czerwenka K, Kubista E: Interleukin-1alpha protein
secretion in breast cancer is associated with poor differenti-
ation and estrogen receptor alpha negativity.  Int J Gynecol Can-
cer 2006, 16:556-559.
10. Singer CF, Kronsteiner N, Hudelist G, Marton E, Walter I, Kubista M,
Czerwenka K, Schreiber M, Seifert M, Kubista E: Interleukin 1 sys-
tem and sex steroid receptor expression in human breast
cancer: interleukin 1alpha protein secretion is correlated
with malignant phenotype.  Clin Cancer Res 2003, 9:4877-4883.
11. Dinarello CA: Biologic basis for interleukin-1 in disease.  Blood
1996, 87:2095-2147.
12. Pociot F, Molvig J, Wogensen L, Worsaae H, Nerup J: TaqI poly-
morphism in the human interleukin-1 beta (IL-1 beta) gene
correlates with IL-1 beta secretion in vitro.  Eur J Clin Invest
1992, 22:396-402.
13. di Giovine FS, Takhsh E, Blakemore Al, Duff GW: Single base poly-
morphism at -511 in the human interleukin-1 beta gene (IL1
beta).  Hum Mol Genet 1992, 1:450.
14. Hulkkonen J, Laippala P, Hurme M: A rare allele combination of
the interleukin-1 gene complex is associated with high inter-
leukin-1 beta plasma levels in healthy individuals.  Eur Cytokine
Netw 2000, 11:251-255.
15. Danis VA, Millington M, Hyland VJ, Grennan D: Cytokine produc-
tion by normal human monocytes: inter-subject variation
and relationship to an IL-1 receptor antagonist (IL-1Ra) gene
polymorphism.  Clin Exp Immunol 1995, 99:303-310.
16. Dewberry R, Holden H, Crossman D, Francis S: Interleukin-1
receptor antagonist expression in human endothelial cells
and atherosclerosis.  Arterioscler Thromb Vasc Biol 2000,
20:2394-2400.
17. Sehouli J, Mustea A, Koensgen D, Lichtenegger W: Interleukin-1
receptor antagonist gene polymorphism in epithelial ovarian
cancer.  Cancer Epidemiol Biomarkers Prev 2003, 12:1205-1208.
18. Palli D, Saieva C, Luzzi I, Masala G, Topa S, Sera F, Gemma S, Zanna
I, D'Errico M, Zini E, Guidotti S, Valeri A, Fabbrucci P, Moretti R,
Testai E, del Giudice G, Ottini L, Matullo G, Dogliotti E, Gomez-
Miguel MJ: Interleukin-1 gene polymorphisms and gastric can-
cer risk in a high-risk Italian population.  Am J Gastroenterol 2005,
100:1941-1948.
19. Lind H, Zienolddiny S, Ryberg D, Skaug V, Phillips DH, Haugen A:
Interleukin 1 receptor antagonist gene polymorphism and
risk of lung cancer: a possible interaction with polymor-
phisms in the interleukin 1 beta gene.  Lung Cancer 2005,
50:285-290.
20. Lindmark F, Zheng SL, Wiklund F, Bälter KA, Sun J, Chang B, Hedelin
M, Clark J, Johansson JE, Meyers DA, Adami HO, Isaacs W, Grönberg
H, Xu J: Interleukin-1 receptor antagonist haplotype associ-
ated with prostate cancer risk.  Br J Cancer 2005, 93:493-497.
21. Lee KM, Park SK, Hamajima N, Tajima K, Choi JY, Noh DY, Ahn SH,
Yoo KY, Hirvonen A, Kang D: Genetic polymorphisms of inter-
leukin-1 beta (IL-1B) and IL-1 receptor antagonist (IL-1RN)
and breast cancer risk in Korean women.  Breast Cancer Res
Treat 2006, 96:197-202.
22. Liu J, Zhai X, Jin G, Hu Z, Wang S, Wang X, Qin J, Gao J, Ma H, Wang
X, Wei Q, Shen H: Functional variants in the promoter of
interleukin-1beta are associated with an increased risk of
breast cancer: a case-control analysis in a Chinese popula-
tion.  Int J Cancer 2006, 118:2554-2558.
23. Snoussi K, Mahfoudh W, Bouaouina N, Ahmed SB, Helal AN,
Chouchane L: Genetic variation in IL-8 associated with
increased risk and poor prognosis of breast carcinoma.  Hum
Immunol 2006, 67:13-21.
24. Smith KC, Bateman AC, Fussell HM, Howell WM: Cytokine gene
polymorphisms and breast cancer susceptibility and progno-
sis.  Eur J Immunogenet 2004, 31:167-173.
25. Iacopetta B, Grieu F, Joseph D: The -174 G/C gene polymor-
phism in interleukin-6 is associated with an aggressive breast
cancer phenotype.  Br J Cancer 2004, 90:419-422.
26. Snoussi K, Strosberg AD, Bouaouina N, Ben Ahmed S, Chouchane L:
Genetic variation in pro-inflammatory cytokines (inter-
leukin-1beta, interleukin-1alpha and interleukin-6) associ-
ated with the aggressive forms, survival, and relapse
prediction of breast carcinoma.  Eur Cytokine Netw 2005,
16:253-260.
27. Grimm C, Berger I, Tomovski C, Zeillinger R, Concin N, Leodolter S,
Koelbl H, Tempfer CB, Hefler LA: A polymorphism of the inter-
leukin-1 receptor antagonist plays a prominent role within
the interleukin-1 gene cluster in vulvar carcinogenesis.  Gyne-
col Oncol 2004, 92:936-940.
28. Hefler LA, Grimm C, Lantzsch T, Lampe D, Leodolter S, Koelbl H,
Heinze G, Reinthaller A, Tong-Cacsire D, Tempfer C, Zeillinger R:
Interleukin-1 and interleukin-6 gene polymorphisms and the
risk of breast cancer in caucasian women.  Clin Cancer Res 2005,
11:5718-5721.
29. Tarlow JK, Blakemore AI, Lennard A, Solari R, Hughes HN, Stein-
kasserer A, Duff GW: Polymorphism in human IL-1 receptor
antagonist gene intron 2 is caused by variable numbers of an
86-bp tandem repeat.  Hum Genet 1993, 91:403-404.
30. Cvetkovic RS, Keating G: Anakinra.  BioDrugs 2002, 16:303-311.
31. Bar D, Apte RN, Voronov E, Dinarello CA, Cohen S: A continuous
delivery system of IL-1 receptor antagonist reduces angio-
Additional file 1
Tables. Table 1. Characteristics in patients with breast cancer. Table 2. 
Genotype and allele frequencies of the four investigated IL1 gene polymor-
phisms in breast cancer patients. Table 3. Survival analysis of IL1 gene 
polymorphisms and prognostic covariates in patients with breast cancer. 
Table 4. Association between interleukin-1 haplotypes and overall survival 
of patients with breast cancer.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2407-9-78-S1.doc]Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Cancer 2009, 9:78 http://www.biomedcentral.com/1471-2407/9/78
Page 6 of 6
(page number not for citation purposes)
genesis and inhibits tumor development.  FASEB J 2004,
18:161-163.
32. Weinreich DM, Elaraj DM, Puhlmann M, Hewitt SM, Carroll NM,
Feldman ED, Turner EM, Spiess PJ, Alexander HR: Effect of inter-
leukin 1 receptor antagonist gene transduction on human
melanoma xenografts in nude mice.  Cancer Res 2003,
63:5957-5961.
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1471-2407/9/78/prepub